Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 12 of 12 entries
View as:

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients with HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05034887 Org: User:
Start: 01/31/22 End: 03/31/29 Due: 03/31/30

Efficacy and Safety of CRT, Durvalumab and Surgery for SST

Phase: N/A Priority: Normal
NCT ID: NCT04465968 Org: User:
Start: 09/01/20 End: 08/31/30 Due: 08/31/31

Lenvatinib and Pembrolizumab Simultaneous Combination Study

Phase: N/A Priority: Normal
NCT ID: NCT03609359 Org: User:
Start: 10/03/18 End: 04/30/21 Due: 04/30/22

TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05646511 Org: User:
Start: 11/21/22 End: 12/31/30 Due: 12/31/31

Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT05394740 Org: User:
Start: 06/06/22 End: 11/30/25 Due: 11/30/26

Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04288999 Org: User:
Start: 10/01/19 End: 10/31/28 Due: 10/31/29

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT07018570 Org: User:
Start: 06/30/25 End: 06/30/31 Due: 06/30/32

Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection

Phase: N/A Priority: Normal
NCT ID: NCT04457297 Org: User:
Start: 07/08/20 End: 12/31/23 Due: 12/31/24

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Phase: N/A Priority: Normal
NCT ID: NCT05694819 Org: User:
Start: 04/17/20 End: 03/31/26 Due: 03/31/27

Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04417192 Org: User:
Start: 12/01/20 End: 06/30/23 Due: 06/30/24

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04745988 Org: User:
Start: 11/11/21 End: 08/31/27 Due: 08/31/28

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

Phase: N/A Priority: Normal
NCT ID: NCT05696548 Org: User:
Start: 07/02/19 End: 12/31/26 Due: 12/31/27